"rationale","uuid:ID","instanceType","id","versionIdentifier"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","7bb8c04d-2a3c-484e-b5a0-60a6a084ed67","StudyVersion","StudyVersion_1","2"
